维普期刊资源整合服务平台（V6.5）

88篇 您的检索式：作者名="ESKENS FA"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Matrix metalloproteinase inhibitors:current developments and future perspectives 显示文摘	Hoekstra R Eskens FA	2001	Oncologist2001，6，：	1
2	Phase Ⅱ study of biweekly administration of paclitaxel and cisplatin in patients with advanced esophageal cancer显示文摘	Polee MB Eskens FA Burg ME	2002	Br Cancer2002，86，5：	1
3	Phase Ⅱ study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus显示文摘	Polee MB Tilanus HW Eskens FA	2003	Ann Oncol2003，14，8：	1
4	Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide,a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumors显示文摘	Eskens FA Dumez H Hoekstra R	2003	Eur J Canceer2003，39，7：	1
5	Phase Ⅰ and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974),a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours显示文摘	ESKENS FA DUMEZ H HOEKSTRA R	2003	Eur J Cancer2003，39，7：	1
6	PhaseⅡstudy of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus显示文摘	Polee MB Tilanus HW Eskens FA	2003	Ann Oncol2003，14，8：	1
7	First - line treament with oxaliplatin and capecitabine in pa- tients with advanced or metastatic oesophageal cancer:a phase Ⅱ study显示文摘	Van Meeten Eskens FA Van Gameren EC	2007	Br J Cancer2007，96，9：	1
8	Phase Ⅱ study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer显示文摘	Polee MB Eskens FA van der Burg ME	2002	Br J Cancer2002，86，5：	1
9	Phase I and pharmacokinet- ic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974),a novel inhibitor of the integrins al- phavbeta3 and alphavbeta5 in patients with advanced solid tu- mours显示文摘	Eskens FA Dumez H Hoekstra R	2003	Eur J Cancer2003，39，7：	1
10	Phase Ⅱ study of hi-weekly administration of paclitaxel and cisplatin in patients with advanced esophageal cancer显示文摘	Polee MB Eskens FA Van der Burg ME	2002	Br J Cancer2002，86，5：	1
11	Pharmacologic study of PKI-166, an epidermal growth factor recap receptor tyrosine kinase inhibitor, inpatients with advanced solid malignancies显示文摘	Floekstra R Dumez H Eskens FA	2005	Clin Cancer Res2005，11，19：	1
12	Angiogenesis inhibitors in clinical development: whereare we now and where are we going显示文摘	Eskens FA	2004	Br J Cancer2004，90，1：	1
13	Phase Ⅱ study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer显示文摘	Polee MB Eskens FA van der Burg ME	2002	Br J Cancer2002，86，5：	1
14	Vascular disrupting agents in clinical development 显示文摘	Hinnen P Eskens FA	2007	Br J Cancer2007，96，8：	1
15	First-line treatment with oxaliplatin and Capecitabine in patients with advanced or metaststic oesophageal cancer: a phase Ⅱ study 显示文摘	Van meerten E Eskens FA Van Gameren EC	2007	Br J Cancer2007，96，9：	1
16	Matrix metalloproteinase inhibitors: current developments and future perspectives显示文摘	Hoekstra R Eskens FA Verweij J	2001	The Oncohgist2001，6，5：	1
17	Phase Ⅱ study of biweekly administration of paclitaxel and cisplatin in patiernswith advanced esophageal cancer显示文摘	Polee MB Eskens FA van der Burg ME	2002	Br J Cancer2002，86，5：	1
18	First-line treatment with oxalipLatin and capecitabine in patients with advanced or metastatic oesophageal cancer:a phase II study显示文摘	Van Meerten E Eskens FA van Gameren EC	2007	Br J Cancer2007，96，9：	1
19	First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer:a phase II study显示文摘	van Meerten E Eskens FA van Gameren EC	2007	Br J Cancer2007，96，9：	1
20	Phase lI study of hi-weekly administration of paclitaxel and cisplatin in pa- tients with advanced ocsophageal cancer显示文摘	Polee MB Eskens FA van der Burg ME	2002	Br J Cancer2002，86，5：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示